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Introduction: In this study, we investigated the effect of the
3-hydroxy-3-methylgutaryl-CoA reductase inhibitor lovastatin, as a
sensitizer of lung cancer cells to ionizing radiation (IR).
Methods: A549 lung adenocarcinoma cells were treated with 0 to
50 M lovastatin alone or in combination with 0 to 8 Gy IR and
subjected to clonogenic survival and proliferation assays. To assess
the mechanism of drug action, we examined the effects of lovastatin
and IR on the epidermal growth factor (EGF) receptor and AMP-
activated kinase (AMPK) pathways and on apoptotic markers and
the cell cycle.
Results: Lovastatin inhibited basal clonogenic survival and prolif-
eration of A549 cells and sensitized them to IR. This was reversed
by mevalonate, the product of 3-hydroxy-3-methylgutaryl-CoA re-
ductase. Lovastatin attenuated selectively EGF-induced phosphory-
lation of EGF receptor and Akt, and IR-induced Akt phosphoryla-
tion, in a mevalonate-sensitive fashion, without inhibition on
extracellular signal-regulated kinase 1/2 phosphorylation by either
stimulus. IR phosphorylated and activated the metabolic sensor and
tumor suppressor AMPK, but lovastatin enhanced basal and IR-
induced AMPK phosphorylation. The drug inhibited IR-induced
expression of p53 and the cyclin-dependent kinase inhibitors p21cip1
and p27kip1, but caused a redistribution of cells from G1-S phase
(control and radiated cells) and G2-M phase (radiated cells) of cell
cycle into apoptosis. The latter was also evident by induction of
nuclear fragmentation and cleavage of caspase 3 by lovastatin in
both control and radiated cells.
Conclusions: We suggest that lovastatin inhibits survival and in-
duces radiosensitization of lung cancer cells through induction of
apoptosis, which may be mediated by a simultaneous inhibition of
the Akt and activation of the AMPK signaling pathways.
Key Words: Lovastatin, Lung cancer, A549 cells, Radiation sensi-
tizer, Apoptosis, Akt, AMPK, Erk, EGFR, Cell cycle, Cleaved
caspase 3.
(J Thorac Oncol. 2011;6: 439–450)
Radiotherapy is a widely used therapy in all stages ofnon-small cell lung cancer (NSCLC). However, NSCLC
demonstrates intrinsic radioresistance that leads to failure of
even high-dose thoracic radiation.1 Therefore, there is an
urgent need for rational development of effective radiation
sensitizers for NSCLC, which are able to inhibit molecular
pathways mediating radiation resistance.
Ionizing radiation (IR) elicits signal transduction lead-
ing to cell survival, apoptosis, and cell cycle regulation.2
IR-induced DNA double-strand breaks are potentially lethal
DNA damages leading to activation of phosphatidylinositol
3-kinase (PI3k)-like family protein kinases such as DNA-
protein kinase and ataxia telangiectasia mutated (ATM).3
ATM mediates phosphorylation of p53 leading to stabili-
zation of this tumor suppressor and cell cycle arrest at the
G1-S or the G2-M check points through induction of the
cip/kip family cyclin-dependent kinase inhibitor (CDKI)
p21cip1.4 p27kip1, another cip/kip family CDKI, functions
independently of the p53-p21cip1 pathway and inhibits
cyclin E-cyclin-dependent kinase 2 complex and cycle
progression through the G1-S checkpoint.4
Recently, we reported that the energy sensor AMP-
activated kinase (AMPK), an established effector of the
tumor suppressor LKB1, is activated by IR in a variety of
epithelial cancer cells.5 IR activates AMPK in LKB1-inde-
pendent but ATM-dependent manner leading to induction of
p53 and p21cip1, cell cycle arrest at the G2-M checkpoint, and
modulation of the sensitivity of cells to IR. IR is also shown
to regulate mediators of the signaling pathway of epidermal
growth factor receptor (EGFR),6,7 a well-established activator
of cancer cell proliferation. IR activates the downstream
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effector pathways of EGFR such as the PI3k—Akt—mam-
malian target of rapamycin (mTOR) and the Raf—mitogen-
activated protein kinase-kinase (Mek1)—mitogen-activated
protein kinase p42/44 (also known as extracellular signal-
regulated kinase [Erk1/2]) pathways. These are known to
mediate cell survival and radiation resistance, gene expres-
sion, and protein synthesis.8,9
Small GTP-binding proteins of the Ras family such as
Ras, Rac, and Rho (A/B) mediate signal transduction down-
stream of EGFR to activate the PI3k-Akt-mTOR and the
Raf-Mek-Erk1/2 pathways. Ras mutations are frequent in
lung cancer, and they occur in both the H- and K-Ras
isoforms and were shown to induce radiation resistance in
vitro.10,11 For that, extensive work is focused on targeting Ras
family members with inhibitors of prenylation, a posttrans-
lational modification required for membrane targeting and
function of Ras.12
Members of the statin family of 3-hydroxy-3-methyl-
gutaryl-CoA (HMG-CoA) reductase inhibitors are widely
used anticholesterol agents that inhibit the conversion of
HMG-CoA to mevalonate, a rate-limiting step of the meva-
lonate—cholesterol biosynthesis pathway.13,14 This pathway
is also vital for the production of farnesyl and geranylgeranyl
moieties required for the posttranslational modification and
function of Ras and Rho, respectively.13 For this reason,
statins have been studied extensively as antitumor agents.
During the past 20 years, a large amount of studies have
demonstrated the antiproliferative and proapoptotic effects of
statins both in vitro and in animal models of cancer. Growth
inhibition, cell cycle arrest, and induction of apoptosis in
cancer cells have been demonstrated convincingly.15 The
interest in these drugs was enhanced by epidemiological
studies indicating that patients on statins may have lower risk
for development of colorectal carcinoma16 and lung cancer.17
The Veterans Affairs Health Care System study17 showed
that use of statins for more than 6 months could offer a 55%
risk reduction on the incidence of lung cancer, indicating that
these agents may have significant chemoprevention action.
Further, in prostate cancer, statin use is suggested to decrease
the risk for advanced and metastatic cancer in epidemiolog-
ical studies,18 to slow disease progression after radical pros-
tatectomy,19 and, importantly, to reduce disease recurrence in
patients treated with curative radiotherapy.20,21
Lovastatin is probably the most widely studied statin in
cancer. It has been shown to possess anticancer properties in
vitro and in vivo.14 The antiproliferative action of lovastatin
has been demonstrated in lung cancer cells,22 but its role as a
potential IR sensitizer or adjunct to radiation has not been
examined in lung cancer models. In this study, we examined
the effects of lovastatin on clonogenic survival of lung cancer
cells treated with or without IR and explored the effects of
this drug on cell cycle, apoptosis, and signaling pathways
involved in IR resistance.
METHODS
Materials
Roswell Park Memorial Institute (RPMI) media, fetal
bovine serum, trypsin, and antibiotic were purchased from
Invitrogen (Burlington, ON). Antibodies against phospho-
EGFR, phospho-Akt, phospho-Erk, p53, phospho-AMPK
-subunit, p21cip1, p27kip1, cleaved caspase 3, actin, and horse-
radish peroxidase-conjugated anti-rabbit secondary antibody
were purchased from Cell Signal Technology (Mississauga, ON,
Canada). Polyvinylidene difluoride membrane was purchased
from Pall Corporation (Port Washington, NY). Lovastatin, me-
valonate, and Hoechst 33258 were purchased from Sigma (To-
ronto, ON). A549 cells were from the American Type Culture
Collection (Manassa, VA).
Cell Culture and Treatments
A549 cells were grown in Roswell Park Memorial
Institute (RPMI) media containing 5 mM glucose, 10%
(vol/vol) fetal bovine serum, and 1% (vol/vol) antibiotic-
antimycotic at 37°C as described previously.23 Cells were
treated with the indicated concentrations of lovastatin 24
hours before radiation.
Clonogenic Assay
A549 cells were subjected to clonogenic assays as
described earlier.5 Briefly, 500 or 1000 cells were seeded into
individual wells of a 6-well plate in triplicate and maintained
at the indicated doses of lovastatin before radiation (2–8 Gy).
After 7 days, cells were fixed and stained with methylene
blue, and viable colonies (50 cells) were counted. Results
are expressed as cell survival fraction compared with un-
treated control. To evaluate radiation sensitization by lova-
statin, data were fitted to the linear quadratic equation using
Graphpad Prism version 5 software (La Jolla, CA) as de-
scribed previously.24
Proliferation Assay
Approximately 2500 cells were seeded into a 96-well
plate and treated with the indicated concentrations of lova-
statin before being exposed to 0, 2, or 8 Gy IR. Ninety-six
hours later, the cells were washed with phosphate-buffered
saline, distilled H2O was added to each well, and the plates
were stored at 80°C until completely frozen. The plates
were then thawed and stained with Hoechst working solution
(20 g/mL Hoechst 33258 in a Tris-Borate-EDTA buffer),
and fluorescence was determined using the Cyto-Fluor Plate
Reader (Applied Biosystems, Toronto, ON, Canada).
Immunoblotting
Twenty micrograms of protein was separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membrane as de-
scribed earlier.23 The primary antibody was detected with
horseradish peroxidase-conjugated anti-rabbit secondary an-
tibody and enhanced chemiluminescent detection reagent.
Cell Cycle Analysis
The propidium iodine method was used as described
previously.5 Cells were treated with lovastatin (10 M)
before treatment with 0 or 8 Gy of IR and incubated for the
indicated times and were then subjected to flow cytometric
cell cycle analysis using a FACScan flow cytometer (Beckton
Dickinson, Mississauga, Canada).
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Immunofluorescence Microscopy
Cells grown on glass coverslips for 24 hours were treated
with lovastatin (10 M) for the indicated times. Then the cells
were stained with Hoechst 33258, and images were obtained as
described previously.5 Quantitation of apoptotic cells (showing
nuclear fragmentation) was performed by counting the average
proportion of apoptotic cells in four high-power fields on each
slide (100 cells counted in each quadrant of each slide). Values
were normalized to the untreated control.
Statistical Analysis
Statistical analyses was performed with unpaired T-
test, using SPSS version 16.0 software (Somers, NY) and
are presented as mean  SEM of at least three separate
experiments.
RESULTS
Lovastatin Inhibits NSCLC Cell Survival and
Enhances the Cytotoxicity of IR
We initiated our studies with clonogenic survival as-
says. Lovastatin alone caused a dose-dependent inhibition of
clonogenic survival in A549 cells (Figure 1A). The drug
began inhibiting clonogenic survival at a dose of 5 M (10%
reduction in survival), inhibited the majority of clonogenic
survival at 25 M (95% reduction in survival), and com-
pletely abolished survival at 50 M (Figure 1A).
Lovastatin sensitized A549 cells to IR (Figure 1B).
Clonogenic assay values were fitted into a linear quadratic
model. Both 5 and 10 M of the drug showed significant
radiosensitization of A549 cells to 2 to 8 Gy of IR. Almost
FIGURE 1. Lovastatin inhibits non-small cell lung cancer cell clonogenic survival and sensitizes cells to ionizing radiation. A,
A549 cells were subjected to clonogenic assays as described in the Methods section. Results from five to eight independent
experiments were normalized to the controls and are shown as the mean  standard error (SE). B, Cells were subjected to
increasing doses of ionizing radiation (IR) after incubation without (L0) or with 5 M (L5) or 10 M lovastatin (L10) lovastatin
and subjected to clonogenic assays. Results from five to six independent experiments were normalized to the controls and are
shown as the mean  SE. C, Cell proliferation was evaluated after treatment with indicated concentrations of lovastatin for 24
hours before treatment with indicated doses of IR. Proliferation was evaluated 96 hours later as described in Methods section. Re-
sults from three independent experiments were normalized to the controls and are shown as the mean  SE. D, Cells were subjected to 2
Gy of IR without or with preincubation with either lovastatin alone (15 M) or mevalonate (100 M) and lovastatin before treatment
with 2Gy IR followed by clonogenic assays. Results are the mean  SEM of three independent experiments.
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 Lovastatin Sensitizes Lung Cancer Cells
Copyright © 2011 by the International Association for the Study of Lung Cancer 441
complete inhibition of clonogenic survival was achieved with
10 M lovastatin in combination with 8 Gy IR. In addition,
we evaluated proliferation through DNA synthesis analysis
using the Hoescht DNA staining method. Five micromolar of
lovastatin inhibited basal cell proliferation (by 33%; com-
pared with 0 Gy control) without affecting significantly the
proliferation levels after IR (Figure 1C). However, at 10 M,
the drug inhibited dramatically cell proliferation in both
control cells and those radiated with 2 or 8 Gy (by 63% and
90%, respectively).
Mevalonate Prevents Lovastatin-Induced
Inhibition of Clonogenic Survival
We used mevalonate to examine the specificity of
lovastatin for the mevalonate-cholesterol synthesis pathway
(Figure 1D). Two gray of IR decreased clonogenic survival
by 44% compared with control. Lovastatin alone (15 M)
inhibited survival by 75% and by 92% when combined with
2 Gy of IR. In these experiments, the higher concentration of
15 M lovastatin was used to examine whether mevalonate is
capable of reversing the effects of even high lovastatin doses.
Mevalonate (100 M) inhibited the lovastatin-induced de-
crease in cell survival in both nonradiated and radiated cells,
suggesting that lovastatin mediates its cytotoxic action solely
through inhibition of the mevalonate synthesis pathway.
Lovastatin Inhibits EGF-Stimulated Activation
of EGFR and Akt
To analyze the mechanism of action of lovastatin, we
examined first its effects on EGF-induced EGFR and down-
stream effector phosphorylation. EGF induced phosphoryla-
tion of EGFR and the Akt and Erk1/2 kinases (Figure 2).
However, lovastatin inhibited EGFR and Akt phosphoryla-
tion, in a dose-dependent fashion, without affecting phos-
phorylation of Erk1/2 (Figure 2).
Modulation of IR-Stimulated Activation of Akt
and AMPK
Control and lovastatin-treated cells were subjected to
increasing doses of IR and were analyzed by immunoblotting.
IR induced a consistent Akt phosphorylation, even with the
lower dose of 2 Gy, but Erk phosphorylation was seen only
after 4 to 6 Gy (Figure 3A–C). Interestingly, lovastatin
abolished the IR activation of Akt but did not affect signifi-
cantly Erk1/2 phosphorylation by IR (Figure 3A–C). The
inhibition of IR-induced Akt phosphorylation by lovastatin
was completely reversed by addition of mevalonate (Figure
3D–E), consistent with clonogenic survival results (Figure
1D). IR also caused a dose-dependent phosphorylation of
AMPK that was accompanied by activation of this kinase
shown by the enhanced phosphorylation of its established
substrate acetyl CoA carboxylase, as observed earlier5 (Fig-
ure 4A–C). Interestingly, lovastatin enhanced significantly
both basal and radiation-induced AMPK phosphorylation and
activity.
Modulation of Cell Cycle Regulators and the
Cell Cycle by Lovastatin
The Akt and AMPK pathways regulate cell cycle
through modulation of p53 and CDKIs p27kip1 and p21cip1.25
FIGURE 2. Lovastatin modulates epidermal
growth factor (EGF)-stimulated Akt phosphoryla-
tion. A, Cells were preincubated with or without
the indicated concentrations of lovastatin for 24
hours before exposure to EGF (1 ng/L). Cells
were then lysed 30 minutes after exposure to
EGF, followed by immunoblotting with antibodies
against phoshorylated EGFR, Akt, Erk, or total ac-
tin. Representative immunoblots are shown. B,
Densitometry values (mean  SEM) from three to
four independent immunoblotting experiments
are displayed in the graph.
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Therefore, we examined whether lovastatin modulates the
levels of these cell cycle inhibitors in control and IR-treated
cells. We observed a significant increase in the expression of
p53, p27kip1, and p21cip1 in response to IR (Figure 5A).
However, lovastatin caused an early inhibition of the IR-
induced expression of p53, p27kip1, and p21cip1, within 24
hours, and for that, we examined the levels of these three cell
cycle regulators up to 96 hours after initiation of treatments.
IR maintained enhanced p53, p27kip1, and p21cip1 levels up to
96 hours later (Figure 5A), but lovastatin inhibited this IR-
FIGURE 3. Lovastatin modulates ionizing radiation (IR)-induced Akt but not Erk phosphorylation. Cells were preincubated
with or without lovastatin (10 M) for 24 hours before exposure to the indicated dose of IR. A, Cells were then lysed 1 hour
after the indicated doses of IR, followed by immunoblotting with indicated antibodies. B and C, Densitometry values of immu-
noblots (mean  SEM) from three independent immunoblotting experiments are shown. D, Cells were treated with or with-
out 15M lovastatin or mevalonate (100 M) for 24 hours before exposure to 2 Gy IR. Cell lysates were subjected to immu-
noblotting. A representative immunoblot is shown. E, Densitometry values (mean  SEM) from three independent
immunoblotting experiments are displayed.
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induced expression, which was almost completely eliminated
at 96 hours.
Effects on Cell Cycle Phase Distribution
Lovastatin alone did not affect significantly the distri-
bution of cells in the phases of the cell cycle in the first 24
hours (Figure 5B). However, lovastatin caused a progressive
significant shift of cells into G0/G1 phase, after 24 hours,
compared with control, and eventually a marked induction of
apoptosis by 72 to 96 hours (24 hours: 2%; 96 hours: 89%).
IR alone caused a significant arrest of cells in G2/M phase at
48 hours (control: 0%; IR: 31%). However, lovastatin atten-
uated IR-induced G2/M arrest and shifted cells into G0/G1
phase and apoptosis (IR G2-M: 31%; Lovastatin IR G2-M:
12%; Figure 5C).
Apoptosis Events Induced by Lovastatin
Finally, we examined the effects of lovastatin and IR on
molecular and morphological markers of apoptosis. Cleaved
caspase 3 levels, an established marker of apoptosis,26 was
analyzed by immunoblotting. Lovastatin alone caused a sig-
nificant increase in cleaved caspase 3 levels and further
potentiated IR-induced expression of this protein at 12 hours
(Figure 7A). IR induction of cleaved caspase 3 dissipated
after 12 hours, but lovastatin enhanced cleaved caspase 3
levels for up to 48 hours later and decreased thereafter. We
analyzed apoptotic events also with morphological analysis
of cells treated with lovastatin for 0 to 72 hours. Consistent
with induction of cleaved caspase 3 (Figure 6A) and the cell
cycle results (Figure 5), lovastatin caused a time-dependent
nuclear fragmentation and induction of apoptotic bodies
(Figure 6B, C).
DISCUSSION
Lovastatin was shown to sensitize human cervix cancer
cells to IR.27 Recently, another statin, simvastatin, was shown
to inhibit small cell lung cancer growth in vitro and in vivo,28
and Bellini et al.29 showed that simvastatin inhibits the
proliferation of A549 lung cancer cells. However, the poten-
tial benefit of combining statins with therapeutic doses of IR
has not been examined in lung cancer models. To our knowl-
edge, this is the first study to demonstrate that lovastatin acts
as a radiation sensitizer in NSCLC cells.
Lovastatin Regulation of Clonogenic Survival in
Control and Radiated Cells
We observed that lovastatin sensitized A549 lung can-
cer cells to therapeutic doses of IR of 2 to 8 Gy (Figure 1).
This was mediated specifically through inhibition of the
mevalonate pathway, as exogenous mevalonate completely
reversed the decrease in lung cancer cell survival observed by
lovastatin (Figure 1D). Fritz et al.27 examined the sensitivity
of a number of cancer cell lines to lovastatin, but only a few
of them showed sensitivity to lovastatin at high doses. HeLa
cells required 20 to 50 M of lovastatin to demonstrate
radiosensitization.27 In this study, lung adenocarcinoma A549
cells showed higher sensitivity to the drug (at 5 and 10 M),
indicating that survival pathways in those cells may be more
dependent on protein prenylation events.
FIGURE 4. Lovastatin modulates ionizing radiation (IR)-induced AMP-activated kinase phosphorylation. A, Cells were preincu-
bated with 10 M lovastatin 24 hours before treatment with the indicated dose of IR, lysed, and subjected to immunoblot-
ting with the indicated antibodies. A representative immunoblot from at least three independent experiments is shown. B,
Cells were preincubated with 10 M lovastatin 24 hours before treatment with 0 or 8 Gy IR. Immunoblotting was preformed
with an antibody against phosphorylated acetyl CoA carboxylase (P-ACC). C, Mean  SEM of densitometry values from three
to four experiments performed in experiment A are shown.
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FIGURE 5. Lovastatin modulates ionizing radiation (IR)-induced expression cell cycle inhibitors and the cell cycle. A, Cells were
treated with 10 M lovastatin with or without a single dose of 8 Gy IR. Cells were then lysed at the indicated times (1–96 hours),
followed by immunoblotting with antibodies that recognize p53, p27kip1, and p21Waf/cip. A representative immunoblot from at
least three independent experiments is shown. B, Cells were treated with 10 M lovastatin for the indicated times, followed by cell
cycle analysis. The results were quantified as % distribution in apoptosis (Apop), G1/S, and G2/M phases. C, Cells were treated
without or with lovastatin were exposed to 0 or 8 Gy IR. Cell cycle analysis was preformed 48 hours later.
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Interestingly, in recent experiments investigating the
effects of lovastatin in SK-MES lung cancer cells, a cell line
of squamous cell carcinoma origin, we have observed an even
greater sensitivity to the drug. These results are shown in
Figure s1 (Supplemental Digital Content) and indicate a 20 to
50 times greater sensitivity of SK-MES cells to lovastatin
compared with adenocarcinoma A549 cells. We are currently
investigating in depth the molecular etiology of this higher
sensitivity of SK-MES cells and its implications. However,
overall, our results demonstrate that lung cancer cells show
significant radiosensitization in response to lovastatin that
should be explored further in preclinical in vivo and in
clinical studies.
As other statins, beyond lovastatin, have shown anti-
proliferative effects in cancer cells,15 one wonders whether
lung cancer cell radiosensitization is a phenomenon unique to
lovastatin. For that, we began to explore the effects of other
statins in A549 cells. In preliminary studies, we observed that
simvastatin is also able to inhibit proliferation of A549 cells
(as shown earlier29) and to sensitize lung cancer cells to IR.
This indicates that radiosensitization is likely a common
effect for this class of agents (Figure s2, Supplemental Digital
Content).
Effects on EGFR and Effector Kinases
Adenocarcinoma A549 cells have a genetic profile that
offers a survival advantage including a K-Ras (Gly12-Ser)
mutation.30 K-Ras activates the PI3k-Akt pathway31 and that
is required for NSCLC tumorigenesis in K-Ras mutant
mice.32 Because it inhibits posttranslational modification of
Ras GTP-binding proteins, lovastatin is expected to abrogate
oncogenic K-Ras and EGFR signaling. In this study, we
observed that lovastatin selectively abrogated EGF-stimu-
lated phosphorylation of EGFR and Akt but not Erk1/2. This
discrepancy was observed also by Mantha et al.33 in SCC9
head and neck tumor cells and suggests that (1) persistent
EGFR phosphorylation may not be required for Erk1/2 acti-
vation and (2) activation of Erk1/2 alone is not adequate to
confer radiation resistance. Our observations suggest that in
lung cancer cells, lovastatin is able to inhibit selectively the
key prosurvival pathway of Akt. This alone could account for
the antiproliferative and proapoptotic effects of the drug.
FIGURE 6. Lovastatin induces cancer cell apoptosis. A, Cells were pretreated with or without lovastatin before exposure to 8
Gy ionizing radiation (IR) and were lysed at the indicated times after radiation (1–72 hours). Cleaved caspase 3 induction was
analyzed by immunoblotting. B, After treatment with lovastatin (10 M) for the indicated times, cells were fixed and stained
with Hoechst, and the nuclear morphology was analyzed with fluorescence microscopy. A representative from three indepen-
dent experiments is shown. C, Nuclear fragmentation was quantitated in three independent experiments as described in the
Methods section. Results are normalized to control untreated cells (0 time with lovastatin).
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Lovastatin Regulation of IR-Activated Signals
Effects on Akt
Similar to EGF-induced signals, lovastatin attenuated
IR-activation of Akt, in a mevalonate-dependent fashion but
did not affect IR-activation of Erk1/2 (Figure 3A–C). Simi-
larly, Mistafa and Stenius34 found that statins primarily target
the Akt pathway to sensitize pancreatic cancer cells to che-
motherapeutic drugs, without effecting Erk. Studies in K-Ras
mutant cells, including A549, have shown that in these cells,
activation of the EGFR-PI3k-Akt pathway confers radiore-
sistance35 and that inhibition of this axis by EGFR inhibitors
sensitizes cells to IR.36 Further, Akt is an established medi-
ator of radiation resistance in many cancer cells.37 The effect
of lovastatin to inhibit IR activation of Akt illustrates a key
property of this drug that luckily mediates its radiosensitiza-
tion action.
Effects on AMPK
A549 cells also carry a point mutation of the LKB1
gene (codon 37 [Q-Ter]) that generates a truncated LKB1
product.38 Therefore, these cells lack LKB1-regulated AMPK
activation, an event that is shown to lead to aberrant activa-
tion of the Akt—mTOR pathway activating protein synthesis
and survival.39 In this study, in agreement with earlier studies
with statins,40 we observed that lovastatin alone activated
AMPK. However, we observed that it also potentiated its
activation by IR (Figure 4C). Recently, we observed that IR
activates AMPK in LKB1 null A549 cells.5 Our observations
in the same cells here suggest that lovastatin also activates
AMPK in an LKB1-independent fashion. These observations
are significant because AMPK is (1) shown to dephosphory-
late and inhibit Akt through increased protein phosphatase 2A
activity41 and (2) to inhibit the mTOR pathway by directly
phosphorylating either its upstream regulator tuberous scle-
rosis 2 or its binding partner Raptor.39
Importantly, AMPK activation also mimics statin ac-
tion because this kinase is known to inhibit HMG-CoA
reductase.42 Therefore, AMPK activation by stimuli such as
IR can work synergistically with lovastatin to augment the
effects of inhibition of the mevalonate pathway. Taking these
notions together with the discussion earlier, lovastatin seems
to be a highly attractive agent with dual potential to enhance
the activity of AMPK and inhibit the Akt pathway through a
number of potential molecular steps.
Modulation of Cell Cycle
Cell Cycle Regulators
IR regulates cell cycle through the induction of p53
and CDKIs, p21cip1 and p27kip1, expression to mediate mainly
an arrest at the G2-M checkpoint.43 We hypothesized that
lovastatin’s antiproliferative effects may involve arrest of the
cell cycle through enhanced expression of p53 and CDKIs.
Although we did observe a potent induction of p53, p21cip1,
and p27kip1 expression by IR alone, lovastatin inhibited IR
induction of p53 and CDKI expression (Figure 5A). This may
be due to either (1) effects of the drug on global gene
transcription and translation or (2) a dependence of p53 and
CDKI expression on specific events inhibited by lovastatin.
Statins were shown to inhibit mTOR-dependent phosphory-
lation or deactivation of the translational repressor eukaryotic
initiation factor 4E-binding protein, leading to suppression of
initiation of cap-dependent mRNA translation.44 It should be
stressed that we did not detect in our study any significant
effects on the levels of any other proteins, including signaling
molecules or actin, suggesting that a global effect on gene
expression is unlikely. Conversely, Akt activity, which is
inhibited by lovastatin, is required for the DNA damage–
induced stabilization of p53,45 and this mechanism may be
active in lovastatin-treated cells. A decrease in p21cip1 levels
with statin treatment was observed by other investigators in
A549 cells.22 Consistent with observations in HeLa cells,27
our work suggests that the mechanism of radiosensitization of
A549 cells is independent of p53 and the CDKIs p21cip1 and
p27kip1.
Cell Cycle
Lovastatin was shown to inhibit cell cycle progression
at G0/G1 phase and promote apoptosis in thyroid cancer,46
breast cancer,47 glioblastoma,48 cervical cancer cells,27 and
squamous cell carcinomas.49 In this study, we observed that
lovastatin treatment shifted cells into G0/G1 phase with a
markedly increased proportion of cells moving into apoptosis
after 48 hours of treatment (Figure 5B). Prolonged treatment
with lovastatin (96 hours) induced marked induction of apo-
ptosis in nonradiated cells and caused a reversal of the G2-M
checkpoint arrest induced by IR and a G0/G1 and apoptotic
distribution (Figure 5B, C). It is possible that inhibition of the
IR-induced G2-M arrest by lovastatin induced radiosensiti-
zation through prevention of DNA repair and induction of
genomic instability.
Induction of Apoptosis
Consistent with the cell cycle analysis results, we
observed that lovastatin alone induced cleaved caspase 3, a
significant contributor to protein degradation. Although IR
caused a reversible induction of this marker that was not
detectable after 24 hours, lovastatin enhanced and prolonged
the IR-induced cleaved caspase 3 formation for up to 72
hours (Figure 6A). Furthermore, morphological analysis ver-
ified a progressive formation of apoptotic bodies with con-
tinued incubation with lovastatin (Figure 6B, C). Overall, our
results are consistent with other studies,22,50 suggesting apo-
ptosis as major mechanism of the cytotoxic action of lova-
statin and suggests that this is also a predominant mode of
action of the drug when combined with radiation in lung
cancer cells.
Potential for Clinical Development in Lung
Cancer in Combination with Radiotherapy
A number of clinical studies explored the potential of
lovastatin to achieve tumoricidal doses in human patients.
Typical doses of lovastatin aiming to control cholesterol
levels in humans are approximately 1 mg/kg/d and are shown
to yield serum concentrations in the range of 0.15 to 0.3
M.51 Early phase dose-escalation studies have explored a
number of regiments, and in a study of 7 consecutive days
treatment, in 4-week cycles, doses up to 25 mg/kg/d were
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tolerated without severe myopathy.51 Ubiquinone is used to
address myopathy. Under these conditions, maximum toler-
ated doses were not reached, and systemic drug concentra-
tions reached 0.1 to 3.92 M.51 In a study with end-stage
head and neck and cervix cancers patients,52 a regiment of 7.5
mg/kg/d for 21 consecutive days in 4-week cycles was
defined as maximum tolerated doses in patients with good
renal function. Although no objective responses were seen in
this study, where lovastatin was used as a single agent, the
authors still reported a 23% rate of stable disease at 3
months,52 which is indeed encouraging in patients with end-
stage disease.
The aforementioned studies suggest that it is possible to
achieve safely tumoricidal and radiosensitizing doses of lo-
vastatin in cancer patients. Our work indicates that some lung
cancer tumors may exhibit sensitivity to lovastatin even in the
high nanomolar range (Figure s1, Supplemental Digital Con-
tent and discussion earlier) making it even more plausible that
lovastatin will sensitize tumors to IR in human patients.
Overall, these data indicate that this drug deserves further
investigation with in vivo preclinical and clinical studies.
Although, other statins may also be able to radiosensitize
lung tumor cells (Figure s2, Supplemental Digital Content
and discussion above), lovastatin remains the best studied
agent in this class, in both the preclinical and the clinical
setting and, therefore, is the most favorable candidate for
further development.
CONLCUSIONS
Figure 7 illustrates our model of the action of lovastatin
in lung cancer cells. Our work suggests that lovastatin is a
promising agent with significant antitumor properties as a
single agent and a radiation sensitizer. Lovastatin seems to
function mainly through induction of apoptosis. This effect
may be mediated by a unique simultaneous inhibition of the
prosurvival Akt and activation of the tumor suppressor
AMPK pathways. This work presents compelling evidence
that support further investigation of lovastatin as a radiation
sensitizer in vivo. Work in animal models of lung cancer will
FIGURE 7. Model of lovastatin-
induced sensitization of lung cancer
cells to radiation. A, Stimulation of
epidermal growth factor receptor
(EGFR) signaling and activation of
Erk and Akt stimulate proliferation
and induce radiation resistance in
lung cancer cells. B, Lovastatin in-
hibits Akt and stimulates activation
of AMPK leading to apoptosis and
radiation sensitization. IR, ionizing
radiation.
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expedite the development of this drug to the clinical setting in
early phase studies in combination with radiotherapy.
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